Lotus Eye Hospital & Institute Ltd (LOTUSEYE) — FY26 Annual Report | 1 September 2026

Lotus Eye Hospital & Institute Ltd reported a consolidated revenue of ₹5,489 lakhs for FY2025-26, up from ₹5,086 lakhs in the prior year, driven by expansion into new centers like Gobichettipalayam. The company recorded a Profit After Tax of [amount context mismatch] lakhs, down from ₹73.93 lakhs previously, due to higher expansion costs. Management highlighted ongoing investments in technology and infrastructure to strengthen clinical capabilities and patient reach. The Board approved a revised remuneration for Managing Director Sangeetha Sundaramoorthy, increasing her monthly pay from ₹3.5 lakhs to ₹6 lakhs effective August 10, 2026, for the remaining term until August 14, 2028. No dividends were declared during the year. The filing details AGM resolutions, including shareholder approvals for director appointments and remuneration revisions, and notes compliance with SEBI regulations despite prior penalties for procedural delays. Key risks include rising operational costs, competitive pressures in ophthalmology, and regulatory compliance challenges.